ARQT Arcutis Biotherapeutics Inc

Price (delayed)

$28.12

Market cap

$1.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.45

Enterprise value

$1.13B

Highlights
Arcutis Biotherapeutics's quick ratio has surged by 130% QoQ and by 43% YoY
Arcutis Biotherapeutics's equity has surged by 86% YoY and by 67% QoQ
Arcutis Biotherapeutics's net income has shrunk by 127% YoY and by 6% QoQ

Key stats

What are the main financial stats of ARQT
Market
Shares outstanding
50.21M
Market cap
$1.41B
Enterprise value
$1.13B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.12
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$143.71M
EBITDA
-$143.14M
Free cash flow
-$139.06M
Per share
EPS
-$3.45
Free cash flow per share
-$2.94
Book value per share
$9
Revenue per share
$0
TBVPS
$9.97
Balance sheet
Total assets
$471.42M
Total liabilities
$20.42M
Debt
$5.05M
Equity
$450.99M
Working capital
$450.66M
Liquidity
Debt to equity
0.01
Current ratio
30.43
Quick ratio
29.15
Net debt/EBITDA
1.99
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-47.9%
Return on equity
-52.1%
Return on invested capital
-101.8%
Return on capital employed
-31.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARQT stock price

How has the Arcutis Biotherapeutics stock price performed over time
Intraday
-1.37%
1 week
1.26%
1 month
9.2%
1 year
-3.93%
YTD
-0.04%
QTD
-2.8%

Financial performance

How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$144.08M
Net income
-$143.71M
Gross margin
N/A
Net margin
N/A
Arcutis Biotherapeutics's net income has shrunk by 127% YoY and by 6% QoQ
The company's operating income has shrunk by 122% YoY and by 5% QoQ

Growth

What is Arcutis Biotherapeutics's growth rate over time

Valuation

What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
3.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ARQT's EPS has soared by 82% YoY and by 9% QoQ
Arcutis Biotherapeutics's equity has surged by 86% YoY and by 67% QoQ
The stock's price to book (P/B) is 36% less than its last 4 quarters average of 4.9

Efficiency

How efficient is Arcutis Biotherapeutics business performance
The ROE has plunged by 99% YoY but it has grown by 14% from the previous quarter
ARQT's return on assets has dropped by 92% year-on-year but it is up by 13% since the previous quarter
The company's return on invested capital rose by 17% YoY and by 16% QoQ

Dividends

What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARQT.

Financial health

How did Arcutis Biotherapeutics financials performed over time
The current ratio has soared by 135% from the previous quarter and by 47% YoY
Arcutis Biotherapeutics's quick ratio has surged by 130% QoQ and by 43% YoY
Arcutis Biotherapeutics's debt is 99% lower than its equity
Arcutis Biotherapeutics's equity has surged by 86% YoY and by 67% QoQ
ARQT's debt to equity has dropped by 50% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.